程序性细胞死亡蛋白配体 -1与程序性细胞死亡蛋白配体 -1抑制剂在垂体腺瘤中的研究进展

垂体腺瘤是垂体最常见的疾病，侵袭性垂体腺瘤和垂体癌对常规诊疗方式效果欠佳，是目前临床治疗的难点。免疫检查点抑制剂是肿瘤免疫治疗新的选择，在垂体腺瘤中的应用受到关注。程序性细胞死亡蛋白配体-1(PD-L1)/程序性死亡蛋白配体-1抑制剂目前研究得较为广泛，现重点阐述PD-L1/PD-L1抑制剂在侵袭性垂体腺瘤中的最新研究进展，以期为临床相关治疗提供参考。

Research progress on PD-L1 and PD-L1 inhibitors in pituitary adenomas

Pituitary adenoma is the most common disease of pituitary gland. Invasive pituitary adenoma and pituitary carcinoma aredifficult to be diagnosed and treated by conventional methods. Immune checkpoint inhibitors are a new option for tumor immunothera-py, whose application in the treatment of pituitary adenomas has attracted much attention, and programmed cell death protein ligand 1(PD-L1) and PD-L1 inhibitors have been extensively studied. This review focuses on the latest research progress on PD-L1/PD-L1 in-hibitors in invasive pituitary adenomas, in order to provide reference for related clinical treatment.